New York (HedgeCo.Net) – In what seems like a strategy that would be employed during a political campaign, Hayman Capital and fund manager J. Kyle Bass are employing a tactic in their pharmaceutical investments. The fund has taken a substantial position in Perrigo (NYSE: PRGO), a manufacturer of over-the-counter pharmaceuticals headquartered in Ireland. According to a recent report from Reuters, PRGO is now Hayman Capital’s second largest equity position.

What is interesting about the move is that PRGO manufactures store-brand OTC products as well as generic prescription pharmaceuticals and Bass has taken aim at six different pharmaceutical companies by filing inter partes review (IPR) petitions which challenge the validity of patented drugs. Bass has filed 13 IPR petitions in 2015 alone. Bass has shorted the big name pharma companies he has filed the IPR petitions against and by taking the long position in PRGO, he has chosen his favorite candidate.

Much like a political manager might do, Bass is essentially trying to cut down the competition so that his candidate looks even better. Only in this case, these are political candidates, they are publicly traded pharmaceutical companies.